Emicizumab promotes factor Xa generation on endothelial cells

Until recently, the treatment of hemophilia A relied on factor (F)VIII replacement. However, up to one-third of patients with severe hemophilia A develop neutralizing alloantibodies that render replacement therapies ineffective. The development of emicizumab, a bispecific antibody that partially mim...

Full description

Saved in:
Bibliographic Details
Published inJournal of thrombosis and haemostasis Vol. 22; no. 6; pp. 1605 - 1615
Main Authors Fager, Ammon M., Ellsworth, Patrick, Key, Nigel S., Monroe, Dougald M., Hoffman, Maureane
Format Journal Article
LanguageEnglish
Published England Elsevier Inc 01.06.2024
Subjects
Online AccessGet full text

Cover

Loading…